About Us
Blog
Contains articles from Dante and our partners discussing the latest research, publications, and updates about genome sequencing.
About Us
Dante Genomics receives grant for a whole genome sequencing project to measure utility of pharmacogenomics in a real, clinical setting
Dante Genomics receives grant for a whole genome sequencing project to measure utility of pharmacogenomics in a real, clinical setting
About Us
Inc. Magazine names Dante Genomics in the Top 20 of the fastest-growing companies in the U.S. and Top 5 in the Northeast
Dante Genomics launches Avanti software
About Us
Dante’s whole genome sequencing lab in Dubai featured in CNN’s Decoded Series on the Human Genome Project
Dante Genomics launches Avanti software
About Us
Dante Genomics launches Avanti Software for a plug-and-play genomic interpretation that takes minutes instead of hours
Dante Genomics launches Avanti software
About Us
Dante Genomics launches doctor ordered, clinical whole genome sequencing in the U.S. in partnership with 1health.io
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
About Us
Al Farabi Medical Laboratories and Dante Genomics announce global partnership for the delivery of Next Generation Sequencing Genomic Testing in the Kingdom of Saudi Arabia
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
About Us
Dante Genomics to present at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
About Us
Longenesis Partners with Dante Genomics to Offer Whole Genome Sequencing Solutions for Women’s Health in Europe
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
About Us
Dante Genomics Unveils Digital Health Population Genomics Program at the United Nations General Assembly Science Summit
Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company’s co-founder and CEO Andrea Riposati presented as an opening speaker on Tuesday, September 27, 2022 at the 77th United Nations General Assembly (UNGA) Science Summit, where he unveiled the Company’s Digital Health Population Genomics Program in Europe, including living labs, which are groundbreaking pilot studies with fast impact on a country’s society and digital health.